Biographie
Marc-André Gagnon est chercheur associé au WHO Collaborating Center on Governance, Accountability and Transparency in the Pharmaceutical Sector. Il détient un doctorat de science politique de l’Université York, un Diplôme d’Études Approfondies en économie de l’École Normale Supérieure de Fontenay/Saint-Cloud et Paris-I Sorbonne, et il a effectué ses études postdoctorales avec le Centre des politiques en propriété intellectuelle de l’Université McGill, ainsi qu’avec le Edmond J. Safra Centre for Ethics à l’Université Harvard. Ses recherches portent sur l’économie politique du secteur pharmaceutique, plus spécifiquement sur l’analyse comparée des régimes d’assurance-santé et d’assurance-médicaments, sur les politiques d’innovation et la propriété intellectuelle dans l’économie des savoirs, de même que sur la corruption institutionnelle dans les secteurs pharmaceutique at biochimique.
Recherche et expertise
– Lead investigator for a SSHRC Insight Grant Catalyst (2021-2026)
Research Topic : Ghost-management in the pharmaceutical and agricultural chemical sectors: Dynamics andimplications for Canadian political economy.
Co-investigators : Louise Vandelac (UQAM); Sergio Sismondo (Queens U);
Kean Birch (York U).
Collaborators : Cecilia Rikap, Paul Thacker, Catherine Riva and Serena Tinari.
With additional funding from the Initiative for Digital Citizen Research to support the goals of the Government of Canada’s approach to protecting democracy and combatting disinformation and other online harms.
– Co-investigator for a Jean-Monnet Networks Grant (2019-2021)
To Build capacity on the study Of European Health Policy. With Katherine Fierlbeck and Tom Jefferson, Marc-Andre Gagnon focuses on Regulation and Transparency in Pharmaceutical Policy. The Summer School organized in May-June 2020 was cancelled due to the pandemic.
Publications
Articles scientifiques
– Testoni FE, García Carrillo M, Gagnon M-A, Rikap C, Blaustein M (2021) Whose shoulders is health research standing on? Determining the key actors and contents of the prevailing biomedical research agenda. PLoS ONE 16(4): e0249661. https://doi.org/10.1371/journal.pone.0249661: 1-17.
– Lexchin J, Bero LA, Davis C, Gagnon MA. Achieving greater independence from commercial influence in research. BMJ. 2021 Mar 9;372: n370. doi: 10.1136/bmj.n370. PMID: 33687982.
– Gagnon MA (2020). Understanding the Battle for Universal Pharmacare in Canada; Comment on “Universal Pharmacare in Canada”. International Journal of Health Policy and Management. Vol. 10 (3) March 2021: pp.168-171, doi: 10.34172/ijhpm.2020.40
– Deborah Gleeson (Principal author), Joel Lexchin, Ronald Labonte, Belinda Townsend, MA Gagnon, Jillian Kohler, Lisa Forman and Ken Shadle. “Analysing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts”. Globalization and Health 15(1), November 2019: 1-17.
– Charbonneau, Mathieu, MA Gagnon. « Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs ». Health Policy 122 (12). December 2018: 1295-1301.
– Lexchin, J, JC Kohler, MA Gagnon, J Crombie, P Thacker, A Shnier. “Combating corruption in the pharmaceutical arena. Indian Journal of Medical Ethics, March 15 2018: 1-6.
– Morgan, Steven G, Marc-André Gagnon, Mathieu Charbonneau, Alain Vadeboncoeur. “Evaluating the effects of Quebec’s private– public drug insurance system”. Canadian Medical Association Journal 189 (40); Oct 10, 2017: E1259-E1263.
– Gagnon, MA (principal author) and Karena Volesky, 2017. “Merger Mania: Mergers and acquisitions in the generic drug sector from 1995 to 2016”. Globalization and Health. 13 (62): 1-7.
– Morgan, Steven G., MA Gagnon, Barbara Mintzes and Joel Lexchin, 2016. “A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada”. Healthcare Policy 12 (1), May 2016.
– Gagnon, MA, 2015. “New Drug Pricing; Does it make any sense?” Prescrire International 24 (162): 192-195. English translation of Gagnon, MA, 2015. « Pourquoi les médicaments sont-ils si chers? Les dérives d’un modèle d’affaires. » Prescrire 35 (380): 457-461.
– Lexchin, Joel and MA Gagnon, 2014. « CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs ». Globalization and Health, Vol. 10 #30, May 2014.
Gagnon, MA, 2013. “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” in Journal of Law, Medicine and Ethics, Vol. 41 #3, September 2013: 571-580.
– Gagnon, MA, 2012. “Corporate influence over clinical research: Considering the
alternatives.” Prescrire International 21(129): 191-194. English translation of Gagnon, MA, 2012. “Recherche Clinique Sous Influence: Penser les Alternatives.” Prescrire (342) (March 2012): 311-314.
– Gagnon, MA, 2012. “L’Aide Publique à L’Industrie Pharmaceutique Québécoise: le
jeu en vaut-il la Chandelle?” Interventions Economiques/Papers in Political Economy
(44): 1-17.
– Gagnon, MA (principal author) and Joel Lexchin, 2008. “The Cost of Pushing Pills: A
New Estimate of Pharmaceutical Promotion Expenditures in the United States.” PLoS Medicine 5(1): 1-6.
– Gagnon, MA, 2007. “Capital, Power & Knowledge according to Thorstein Veblen:
Reinterpreting the Knowledge-Based Economy.” Journal of Economic Issues 41(2): 593-
600.
Chapitres de livres
– Gagnon, MA, 2021. "Ghost management as a central feature of accumulation in corporate capitalism: the case of the global pharmaceutical sector". Chapter from Marlène Benquet and Théo Bourgeron (ed.) Accumulating Capital Today: Contemporary Strategies of Profit and Dispossessive Policies. New York: Routledge: pp.163-177.
– Gagnon, MA, Matthew Herder, Janice Graham, Katherine Fierlbeck and Anna Danyliuk, 2021. “Clinical trial data transparency in Canada: Mapping the Progress from Laggard to Leader”. Chapter from Katherine Fierlbeck, Janice Graham and Matthew Herder (eds.) Transparency, Power, and Influence in the Pharmaceutical Industry. Toronto: University of Toronto Press: pp. 114-128.
– Gagnon, MA, 2021. “The Political Economy of Influence; Ghost-management in the Pharmaceutical Sector”. Chapter from Katherine Fierlbeck, Janice Graham and Matthew Herder (eds.) Transparency, Power, and Influence in the Pharmaceutical Industry. Toronto: University of Toronto Press: pp. 159-183.
– Gagnon, MA, 2017. « Financing the Public Provision of Prescription Drugs in Canada: Comparison and Assessment of Financing Options » in Katherine Graham and Allan Maslove (eds) How Ottawa Spends 2017-2018; Canada@150. Ottawa: Carleton University, October 2017.
– Gagnon, MA, 2016. “Shaping the social determinants of value through economic ghostmanagement: an institutionalist approach to capital accumulation.” Published in Tae-Hee Jo and Frederic S. Lee (eds). Marx, Veblen, and the Foundations of Heterodox Economics: Essays in Honor of John F. Henry. London and New York: Routledge: pp.228-251.
– Gagnon, MA (principal author) and Dimitri della Faille, 2013. “Thorstein Veblen:
Economista Iconoclasta.” Published in P.P. Poggio (dir.) L’altronovecento. Comunismo eretico e pensiero critico. Vol 3: Il Capitalismo Americano E I Suoi Critici. Milano: Jaca Book.
– Gagnon, MA, 2012. “Les Droits de Propriété Intellectuelle sont-ils un écueil pour la modernité industrielle? La cas des brevets dans l’industrie pharmaceutique” in Marie-Pierre Boucher (dir.) La Propriété et ses Multiples. Montreal : Nota Bene: 201-250.
– Gagnon, MA, 2004. “La main visible de la propriété intellectuelle contre l’intérêt général: Les formes disciplinaires du néolibéralisme,” in La Régulation Néolibérale: Crise ou ajustement?” Edited by Raphael Canet and Jules Duchastel. Montreal: Athéna Éditions; pp.175-200.
– Gagnon, MA, 2002. “Mercantilisme,” in Relations Internationales: Théories et Concepts. Ed. Évelyne Dufault, Guillaume Dufour, and Alex MacLeod. Montréal: Athéna Éditions; 128-130.
– Gagnon, MA, 2000. “Les réseaux de l’internationalisme statistique (1885-1914),” in Jean-Pierre Beaud and Jean-Guy Prévost (dir.) L’ère des chiffres: systèmes statistiques et traditions nationales. Québec: Presses de l’Université du Québec; 181-220.
Rapports
– MA Gagnon. La régulation des prix des médicaments au Canada et au Québec. Document préparé dans le cadre de la poursuite Merck Canada Inc. c. Procureur général du Canada. Document soumis au procureur général du Canada, 13 mars 2020.
– MA Gagnon (principal author) and Sidney Wolfe. 2015. Mirror, Mirror on the Wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with U.S. government programs. Report for Public Citizen and Carleton University’s School of Public Policy and Administration. Policy Brief, July 23 2015: 19 p.: https://carleton.ca/sppa/wp-content/uploads/Mirror-Mirror-Medicare-Part-D-Released.pdf.
Steven G. Morgan, Danielle Martin, MA Gagnon, Barbara Mintzes, Jamie R. Daw and Joel Lexchin. 2015. Pharmacare 2020; The Future of Drug Coverage in Canada. Published by the Pharmaceutical Policy Research Collaboration, University of British Columbia. July 15 2015: https://pharmacare2020.ca/learn-more
– MA Gagnon. A Roadmap to Rational Pharmacare Policy in Canada. Ottawa: Canadian Federation of Nurses Unions. August 2014.: https://nursesunions.ca/wp-content/uploads/2017/05/Pharmacare_FINAL.pdf
MA Gagnon (principal author) and Guillaume Hébert. “The Economic Case for
Universal Pharmacare.” Ottawa: IRIS and CCPA, September 2010: https://www.policyalternatives.ca/publications/reports/economic-case-universal-pharmacare.
Enseignements et expériences professionnelles
Professeur invité :
July 2016 - July 2017 : University of Ottawa: Visiting Professor with the Centre on Health Law, Policy and Ethics.
Summer 2014: Université Montesquieu Bordeaux-IV (France): Visiting Professor with the Groupe de Recherche en Économie Théorique et Appliquée.
À l’Université Carleton :
– PhD course in public policy:
PADM 6010: Current Issues in Public Policy (Fall 2020, Fall 2021)
Graduate courses in public policy :
– PADM 5672: Policy Seminar on Pharmaceutical Policy (Summer 2012, 2013, 2015, Fall 2018, Winter 2020)
– PADM 5228: Social Policy (Summer 2011, Winter 2012, Fall 2012, Fall 2013, Fall 2015, Fall 2017, Fall 2019, Winter 2021)
– PADM 5129: Capstone Seminar (Winter 2018, Winter 2019, Winter 2020, Winter 2021)
– PADM 5120: Modern Challenges to Governance (Fall 2020)
– PADM 5115: Intro to State and Society (Winter 2011, Fall 2011, Winter 2012, Winter 2013, Winter 2014 (twice), Winter 2015 (twice), Fall 2015, Winter 2016)
Graduate course in political economy :
– PECO 5001: Methodology in Political Economy (Winter 2018, Winter 2019)
Undergraduate course with Arthur Kroeger College of Public Affairs:
– PAPM 1000: Introduction to public affairs and policy management: History of economic thought (Winter 2013, Winter 2014, Winter 2015, Winter 2016, Winter 2018, Winter 2019, Winter 2020)
À l’Université de Bordeaux-IV :
Cour de doctorat en économie pour le Groupe de Recherche en Économie Théorique et Appliquée : Capital, science et pouvoir : les dynamiques d’accumulation dans l’économie du savoir (Été 2014).
À l’Université McGill :
Graduate course at Faculty of Law: CMPL 605: Regulation, Technology and Society (Winter 2010)
À l’Université du Québec à Montréal :
Cours de Maîtrise : POL 8010: Théorie du politique (Automne 2007, Political Science, Université du Québec à Montréal)
Prix et bourse
– Public Commentary Award, Faculty of Public Affairs, Carleton University, 2015
– Ethel Meade Award for Excellence in Healthcare Research, from Ontario Health Coalition, 2014
– “Rising Star Award” from the Institute of Health Services and Policy Research, 2010
– Yumiko Iida Memorial PhD Prize for best dissertation in political science, 2010
– Excellence Award by the Union of Lecturers at University of Montreal, 2008
Activités et conférences
Principales entrevues :
– “Pourquoi le Canada n’a-t-il pas le contrôle de ses vaccins contre la COVID-19? ». Interview for Bien Entendu, Radio-Canada, June 17 2021.
– “What is the Dominant Biomedical Research Agenda and Industry’s Massive Influence”. Interview for the Causes or Cures Podcast, May 15 2021.
– « Coronavirus: Encadrer la course aux traitements ». Interview/Podcast for the Radio Show ¨Ca s’explique", Radio-Canada, 7 avril 2020.
– « Médicaments : Facturer trois fois ses honoraires pour un seul et même geste ». Interview for the TV show La Facture on Radio Canada. March 3 2019.
– « Les ratés de l’assurance-médicaments au Québec ». Interview for RDI Économie (Radio-Canada). 14 novembre 2018.
– « Opioïdes : Le marketing d’une épidémie ». Interview for TV Show Enquête at Radio-Canada, 8 novembre 2018.
Couverture médiatique
January 27, 2021
– Canadian politicians struggle to come to grips with the global vaccine race, Social Sharing, CBC
February 3, 2021
– Was the global vaccine race inevitable?, Politico
February 3, 2021
– Montreal’s new vaccine plant will be late, but useful, observers say, Montreal Gazette
February 12, 2021
– Momentum grows for vaccine technology-sharing as shortages worsen, Globe and Mail
March 18, 2021
– White House says U.S. plans to send 1.5 million doses of AstraZeneca vaccine to Canada, CBC
May 6, 2021
– Canada to take part in talks over COVID-19 vaccine patent waivers, but won’t state its position, Globe and Mail
January 10, 2020
– What needs to change in the Canadian pharmaceutical industry, CTV News
September 11, 2020
– Big Pharma’s Game of Control, The American Prospect
September 29, 2020
– Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing, Newsweek
February 4, 2019
– Just price for drugs: the eleventh hour, The Hill Times
February 9, 2019
– U.S. PhRMA’s fight to prevent lower Canadian drug prices, CBC
August 4, 2019
– Canadians Respond To U.S. Medication Import Plans, KRUC
October 3, 2019
– National pharmacare debate alive and well in Canada. But will it happen?, Global News
January 6, 2018
– New contender for world’s most expensive drug costs 0,000 US, CBC
February 2, 2018
– MPs mum about possibility of national drug plan, CBC
February 3, 2018
– The real story behind the sudden drop in Canada’s drug prices, CBC
September 6, 2018
– How to make medicine more accessible, Inquirer.
March 26, 2018
Number of people using catastrophic drug coverage has tripled, Ontario study finds, CBC
April 20, 2018
– Are cures bad for the drug business?, CBC
May 23, 2018
– The history of why Canada’s health care system falls short, Macleans
July 18, 2018
– Should employers share potential tax burden for pharmacare?, Benefits Canada
November 24, 2018
– Canada has found the key to lowering drug prices, but it won’t be used any time soon, CBC
November 30, 2017
– La bonne gouvernance et la lutte contre la corruption dans le secteur de la santé, L’Économiste
December 13, 2017
– The missing Alzheimer’s pill, Politico
March 7, 2016
- Pensioenfondsen blokkeren prijsverlaging levensreddend medicijn, BNNVARA
April 22, 2015
– Drug companies using doctors, discount cards to skirt generic substitutions, CBC
September 28, 2015
– Here’s one fix for high drug prices, CNN Business
Présentations vidéo
– June 2 2021 (Montreal) :« Quand les brevets font barrage ». Présentation pour « Au cœur des sciences », Université du Québec à Montréal.
– May 26 2021 (Suisse-France-Tunisie-Canada) : Comprendre l’économie politique fantôme dans le secteur pharmaceutique. Présentation pour le Global Investigative Journalism Network.
– April 19 2021(Ottawa): Presentation on “Canada’s International Trade and Investment Policy: Selected Considerations Concerning COVID-19 Vaccines”. Testimony for the Standing Committee on International Trade (CIIT). House of Commons, Government of Canada.
– February 2 2021 (Montreal): « Justice et transparence dans le domaine du médicament ». Organisé par le Centre de Recherche en Droit Public de l’Université de Montréal, coordonné par Laurence Largenté.
– February 1 2021(Ottawa): Presentation on“Emergency Situation Facing Canadians in Light of the Second Wave of the COVID-19 Pandemic”. Testimony for the Standing Committee on Health. House of Commons, Government of Canada.
– May 26 2020 (Ottawa): "The Battle for Universal Pharmacare in Canada". Webinar for Group of 78.